Moderna and Merck shares plummeted after data on the companies' personalized melanoma vaccine wasn't enough to prove to investors that a new era of cancer treatments has arrived. Michelle Fay Cortez has more on "Bloomberg The Close." (Source: Bloomberg)
Moderna and Merck shares plummeted after data on the companies' personalized melanoma vaccine wasn't enough to prove to investors that a new era of cancer treatments has arrived. Michelle Fay Cortez has more on "Bloomberg The Close." (Source: Bloomberg)
<iframe src="https://statesidedaily.com/embed/cluster/47bee6f29b9af8ae4b050207c35fa153226fbbca" width="100%" height="320" style="border:0;max-width:680px" loading="lazy" title="Moderna, Merck Fall After Melanoma Data Leak"></iframe>